A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Alabama
-
Jasper, Alabama, Yhdysvallat, 35501
- Jasper Summit Research, LLC
-
-
Arizona
-
Phoenix, Arizona, Yhdysvallat, 85006
- Pulmonary Associates, PA
-
-
California
-
Fullerton, California, Yhdysvallat, 92835
- California Research Medical Group, Inc.
-
Los Angeles, California, Yhdysvallat, 90095
- UCLA David Geffen School of Medicine
-
Riverside, California, Yhdysvallat, 92506
- Integrated Research Group
-
Sacramento, California, Yhdysvallat, 95819
- Capital Allergy & Respiratory Disease Center
-
San Diego, California, Yhdysvallat, 92120
- Institute of HealthCare Assessment, Inc.
-
-
Florida
-
Clearwater, Florida, Yhdysvallat, 33765
- Clinical Research of West Florida
-
Tampa, Florida, Yhdysvallat, 33603
- Clinical Research of West Florida
-
-
Georgia
-
Austell, Georgia, Yhdysvallat, 30106
- Georgia Clinical Research
-
Lawrenceville, Georgia, Yhdysvallat, 30046
- Gwinnett Biomedical Research
-
-
Kansas
-
Topeka, Kansas, Yhdysvallat, 66606
- Veritas Clinical Specialities, LTD
-
-
Minnesota
-
Minneapolis, Minnesota, Yhdysvallat, 55407
- Minnesota Lung Center
-
-
North Carolina
-
Charlotte, North Carolina, Yhdysvallat, 28207
- American Health Research
-
Raleigh, North Carolina, Yhdysvallat, 27607
- North Carolina Clinical Research
-
-
Ohio
-
Cincinnati, Ohio, Yhdysvallat, 45242
- New Horizons Clinical Research
-
-
Oregon
-
Medford, Oregon, Yhdysvallat, 97504
- Clinical Research Institute of Southern Oregon, PC
-
Medford, Oregon, Yhdysvallat, 97504
- Sunstone Medical Research LLC
-
Portland, Oregon, Yhdysvallat, 97202
- Allergy Associates Research Center
-
-
South Carolina
-
Greenville, South Carolina, Yhdysvallat, 29615
- Upstate Pharmaceutical Research
-
Greenville, South Carolina, Yhdysvallat, 29615
- Greenville Pharmaceutical Research, Inc
-
Spartanburg, South Carolina, Yhdysvallat, 29303
- South Carolina Pharmaceutical Research
-
Union, South Carolina, Yhdysvallat, 29379
- CU Pharmacuetical Research
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- Baylor College of Medicine
-
New Braunfels, Texas, Yhdysvallat, 78130
- Central Texas Health Research
-
-
Virginia
-
Richmond, Virginia, Yhdysvallat, 23225
- Pulmonary Associates of Richmond, Inc.
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Male and female subjects age 35 through 75 years, inclusive.
- A clinical diagnosis of moderate to severe COPD according to GOLD guidelines (2011).
- Current smokers or ex-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, or equivalent).
- Post-bronchodilator (following inhalation of ipratropium bromide MDI) FEV1 ≥ 30% and ≤ 70% of predicted normal value during the Screening Period.
- Post-bronchodilator (following inhalation of ipratropium bromide MDI) FEV1/FVC ratio < 0.70 during the Screening Period.
- Post-bronchodilator (following inhalation of ipratropium bromide MDI) improvement in FEV1 ≥ 12% and ≥ 100 mL during the Screening Period.
- Ability to perform reproducible spirometry according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines (2005).
Subject, if female ≤ 65 years of age and of child bearing potential, must have a negative serum pregnancy test at screening. Females of childbearing potential must be instructed to and agree to avoid pregnancy during the study and must use an acceptable method of birth control:
- a. An oral contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or injectable contraceptive for at least 1 month prior to entering the study with continued use throughout the study and for thirty days following study participation.
- b. Barrier method of contraception, eg, condom and/or diaphragm with spermicide while participating in the study.
- c. Abstinence.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Current evidence or recent history of any clinically significant and unstable disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data; including but not limited to cardiovascular disease, myocardial infarction, cardiac failure, uncontrolled hypertension, life-threatening arrhythmias, uncontrolled diabetes, neurologic or neuromuscular disease, liver disease, gastrointestinal disease or electrolyte abnormalities.
- Current evidence or history of clinically significant abnormal cardiac rhythm and/or conduction findings, including Holter monitoring results during the Screening Period.
- Concomitant pulmonary disease or primary diagnosis of asthma.
- History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma of the skin
- Recent history of COPD exacerbation requiring hospitalization or need for increased treatments for COPD within 6 weeks prior to the Screening Period.
- Use of daily oxygen therapy > 10 hours per day.
- Use of systemic steroids within 3 months prior to the Screening Period.
- Respiratory tract infection within 6 weeks prior to or during the Screening Period.
- History of tuberculosis, bronchiectasis or other non-specific pulmonary disease.
- History of urinary retention or bladder neck obstruction type symptoms.
- History of narrow-angle glaucoma.
- Prolonged QTc interval (> 450msec for males and > 470msec for females) during the Screening Period, or history of long QT syndrome.
- Recent history (previous 12 months) of excessive use or abuse of narcotic/illegal drugs.
- History of hypersensitivity or intolerance to β2-agonists or anticholinergics.
- Participation in another investigational drug study where drug was received within 30 days prior to the Screening Period.
- Female subject who is pregnant or lactating
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Placebo Comparator: EP-101 Placebo
EP-101 Placebo AM + EP-101 Placebo PM
|
EP-101 Placebo AM + EP-101 Placebo PM
Muut nimet:
|
|
Kokeellinen: EP 101 12.5 mcg
EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
|
EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
Muut nimet:
|
|
Kokeellinen: EP-101 25 mcg
EP-101 25 mcg AM + EP-101 25 mcg PM
|
EP-101 25 mcg AM + EP-101 25 mcg PM
Muut nimet:
|
|
Kokeellinen: EP-101 50 mcg
EP-101 50 mcg AM + EP-101 50 mcg PM
|
EP-101 50 mcg AM + EP-101 50 mcg PM
Muut nimet:
|
|
Kokeellinen: EP-101 100 mcg
EP-101 100 mcg AM + EP-101 100 mcg PM
|
EP-101 100 mcg AM + EP-101 100 mcg PM
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1)
Aikaikkuna: Baseline and Day 29
|
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Trough FEV1 was defined as the mean of the spirometry values collected at 23 hours 30 minutes and 24 hours after the in-clinic morning dose (i.e.
approximately 12 hrs after the previous evening dose).
|
Baseline and Day 29
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
The Standardized Change From Baseline FEV1 AUC(0-12)
Aikaikkuna: Day 28
|
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
|
Day 28
|
|
The Standardized Change From Baseline FEV1 AUC(12-24)
Aikaikkuna: Day 28
|
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
|
Day 28
|
|
The Peak FEV1 Change From Baseline
Aikaikkuna: Day 28
|
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.
Peak FEV1 is defined as the highest postdose FEV1 value within 4 hrs after the morning dose.
|
Day 28
|
|
The Number of Subjects With Treatment-emergent Adverse Events
Aikaikkuna: Baseline up to Day 28
|
Treatment-emergent adverse events were those which first occurred or increased in severity or relationship to study drug after the first dose of double-blind study drug.
|
Baseline up to Day 28
|
|
The Number of Subjects With Treatment-emergent Serious Adverse Events
Aikaikkuna: Baseline up to Day 28
|
Treatment-emergent serious adverse events were those which first occurred or increased in severity or relationship to study drug after the first dose of double-blind study drug.
|
Baseline up to Day 28
|
|
The Number of Subjects With Treatment-emergent Adverse Events Leading to Study Medication Discontinuation
Aikaikkuna: Baseline up to Day 28
|
Treatment-emergent adverse events were those which first occurred or increased in severity or relationship to study drug after the first dose of double-blind study drug.
|
Baseline up to Day 28
|
|
The Percentage of Subjects With Treatment-emergent Adverse Events
Aikaikkuna: Baseline up to Day 28
|
Treatment-emergent adverse events were those which first occurred or increased in severity or relationship to study drug after the first dose of double-blind study drug.
|
Baseline up to Day 28
|
|
The Percentage of Subjects With Treatment-emergent Serious Adverse Events
Aikaikkuna: Baseline up to Day 28
|
Treatment-emergent serious adverse events were those which first occurred or increased in severity or relationship to study drug after the first dose of double-blind study drug.
|
Baseline up to Day 28
|
|
The Percentage of Subjects With Treatment-emergent Adverse Events Leading to Study Medication Discontinuation
Aikaikkuna: Baseline up to Day 28
|
Treatment-emergent adverse events were those which first occurred or increased in severity or relationship to study drug after the first dose of double-blind study drug.
|
Baseline up to Day 28
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Opintojohtaja: Respiratory Medical Director, MD, Sunovion Respiratory Development
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Todellinen)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- EP-101-04 (SUN101)
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .